Combination immunotherapy with 4-1BBL and CTLA-4 blockade for the treatment of prostate cancer.
Immune regulation has been shown to be involved in the progressive growth of some murine tumours. Interruption of immune regulatory pathways via activation of 4-1BB or cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blockade appears to be a promising strategy for cancer immunotherapy. In this study, we examined the effectiveness of 4-1BBL-expressing tumor cell vaccine in combination with CTLA-4 blockade on rejection of murine prostate cancer RM-1. We found that the combination of both a vaccine consisting of 4-1BBL-expressing RM-1 cells and CTLA-4 blockade resulted in regression of RM-1 tumors and a significant increase in survival of the tumour cell recipients, compared to that of either treatment alone. The combined vaccination resulted in higher CTL against RM-1 cells and increased secretion of IFN-γ, TNF-α,  and IL-2 in the mix-cultured supernatant. These results suggest that combining activation of 4-1BB and blockade of CTLA-4 may offer a new strategy for prostate cancer immunotherapy.
Renmin Hospital of Wuhan University, Wuhan 430060, China.
Kuang
K
Youlin
Zhang
Z
Li
Weng
W
Xiaodong
Liu
L
Xiuheng
Zhu
Z
Hengchen
D053330:4-1BB Ligand / Q000235:genetics / Q000378:metabolism*; D000818:Animals; D000906:Antibodies / Q000008:administration & dosage* / Q000276:immunology / Q000627:therapeutic use; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors* / Q000276:immunology; D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000276:immunology / Q000627:therapeutic use; D002460:Cell Line; D002478:Cells, Cultured; D006801:Humans; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D011471:Prostatic Neoplasms / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D053330:4-1BB Ligand; D000906:Antibodies; D060908:CTLA-4 Antigen; D019496:Cancer Vaccines